Earthquakes, investing in drugs, and how to be decent in Venture Capital.

Sound Bioventures’ Managing Partner Johan Kördel was recently interviewed by Jonas Söderström from BioStock for the latest episode of their Health and Wealth podcast series.

The discussion included Johan’s journey from scientist to seasoned life science investor, the importance of risk management, why a portfolio approach is key when you invest in drug development, and the art of ethical venture capital and its importance to Sound Bioventures.

🎧 You can watch the podcast here: https://www.youtube.com/watch?v=lMphDJCElGM

Latest news

Theolytics Appoints David Apelian MD, PhD, MBA as CEO

2024.12.172024.12.17 / David Apelian MD PhD MBA, an experienced CEO with significant development and regulatory experience in virology and immune-oncology joins Theolytics Dr Apelian joins as the company advances its f ...

Theolytics Doses First Patient in Phase I/IIa Trial of THEO-260 in Ovarian Cancer

2024.11.192024.11.19 / THEO-260 lyses cancer cells and cancer associated fibroblasts whilst alleviating immune suppression in preclinical studies. THEO-260 is a mechanistically novel oncolytic immunotherapy developed to ...

VarmX announces appointment of John Glasspool as CEO

2024.11.122024.11.12 / Leadership team fully strengthened to drive next phase of development Leiden, The Netherlands, 12 november 2024 VarmX, a biotech company developing innovative approaches for the bypass of direc ...